| 1 |
Wang W， Medeiros LJ. Castleman disease ［J］. Surg Pathol Clin， 2019，12（3）: 849-863.
|
| 2 |
赵酉璐， 王文生， 岑溪南， 等. 表现为POEMS 综合征的Casleman病伴肾损害一例并文献复习 ［J/OL］. 中华临床医师杂志（电子版），2017， 11（17）: 2206-2210.
|
| 3 |
Lyapichev KA， You MJ， Vega F， et al. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging ［J］. Virchows Arch， 2020， 477（3）: 437-444.
|
| 4 |
Abdel-Reheim FA， Koss W， Rappaport ES， et al. Coexistence of Hodgkin’s disease and giant lymph node hyperplasia of the plasmacell type （Castleman’s disease） ［J］. Arch Pathol Lab Med， 1996，120（1）: 91-96.
|
| 5 |
Momoi A， Kojima M， Sakai T， et al. IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease:report of a case ［J］. Int J Hematol， 2013， 97（2）: 275-279.
|
| 6 |
Haque S， van Kirk R. Three patients with both Hodgkin's lymphoma and Castleman’s disease: Clinicopathologic correlations and lack of association with HHV-8 ［J］. Indian J Med Paediatr Oncol， 2009， 30（2）:76-79.
|
| 7 |
Abdull Gaffar B， Seliem RM. Hodgkin lymphoma with an interfollicular growth pattern: A clinicopathologic study of 8 cases ［J］.Ann Diagn Pathol， 2018， 33: 30-34.
|
| 8 |
Ma’koseh M， Al-Ibraheem A， Almasri N， et al. Classical Hodgkin lymphoma on the background of Castleman disease: a case report ［J］.Cureus， 2023， 15（9）: e44930.
|
| 9 |
Reddy SK， Rekha JS， Jacob SE， et al. Diagnostic issues in a case of hodgkin lymphoma with castleman like features ［J］. Indian J Hematol Blood Transfus， 2014， 30（Suppl 1）: 386-389.
|
| 10 |
寿娟， 龙艳丽， 粟凤， 等. Castleman 病继发霍奇金淋巴瘤临床病理分析并文献复习 ［J］. 华中科技大学学报（医学版）， 2017， 46（5）:612-614.
|
| 11 |
Phulware RH， Ramteke P， Yadav R， et al. Cytology of Castleman's disease （hyaline-vascular type） masquerading as Hodgkin's lymphoma［J］. Am J Blood Res， 2022， 12（6）: 196-200.
|
| 12 |
Ekwere TA， Eziagu UB. Multicentric plasma-cell type Castleman disease masquerading as Hodgkin lymphoma: a case report ［J］. J Lab Physicians， 2020， 12（3）: 225-229.
|
| 13 |
Ibrahim EM， Kazkaz GA， Abouelkhair KM， et al. Increased risk of second lung cancer in Hodgkin’s lymphoma survivors: a meta-analysis［J］. Lung， 2013， 191（1）: 117-134.
|
| 14 |
Lin L， Wang D， Chen H. The characteristics and survival of second primary lung cancer after Hodgkin’s lymphoma: A comparison with first primary lung cancer using the SEER database ［J］. PLoS One，2023， 18（5）: e0285766.
|
| 15 |
Petrusevska M， Stavridis IP， Mladenovska K， et al. Secondary Hodgkin lymphoma and myelodysplastic syndrome （mds） after paclitaxelcarboplatin treatment in a patient with small cell lung cancer ［J］. Pril（Makedon Akad Nauk Umet Odd Med Nauki）， 2017， 38（3）: 97-103.
|
| 16 |
金晶， 王彬， 刘芳， 等. 肺腺癌切除术后肺部非霍奇金淋巴瘤1 例［J］. 浙江医学， 2022， 44（2）: 199-200.
|
| 17 |
Oi I， Saito Z， Ito T， et al. Simultaneous regression of non-small cell lung cancer and orbital extranodal marginal zone lymphoma with chemoradiotherapy for lung cancer ［J］. Respirol Case Rep， 2023，11（7）: e01171.
|
| 18 |
Turbatu A， Dobrea C， Stoian M， et al. Tumor microenvironment in Hodgkin lymphoma: novel prognostic factors for assessing disease evolution ［J］. J Med Life， 2023， 16（8）: 1201-1210.
|
| 19 |
Liu L， Wang C， Li S， et al. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review ［J］. Transl Lung Cancer Res，2021， 10（9）: 3823-3839.
|
| 20 |
Sengul Samanci N， Yılmaz U， Bedir S， et al. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation ［J］. J Oncol Pharm Pract， 2020， 26（8）:2042-2046.
|
| 21 |
Natori D， Ozasa H， Shima Y， et al. Successful treatment of lung cancer coexisting with B-cell lymphoma with pembrolizumab following rituximab-included chemotherapy: A case report ［J］. Mol Clin Oncol，2024， 20（4）: 33.
|